SNDX News and Press, Syndax Pharmaceuticals Inc. From 08/11/23

2023-08-11 14:55:42 ET BofA Securities has initiated coverage of Kura Oncology ( NASDAQ: KURA ) with a buy rating, commenting that it sees the stock as undervalued given the long-term revenue potential of its lead drug candidate ziftomenib, which is being developed as a treatment fo...

2023-08-05 21:08:08 ET Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Conference Call August 3, 2023, 4:30 pm ET Company Participants Sharon Klahre - Head, IR Michael Metzger - CEO Neil Gallagher - President & Head, R&D Keith Goldan - CFO Pe...

2023-08-03 16:52:53 ET Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q2 GAAP EPS of -$0.64 beats by $0.09 . As of June 30, 2023, Syndax had cash, cash equivalents, and short- and long-term investments of $418.3 million and 69.7 million common shares and p...

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update PR Newswire – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivota...

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 PR Newswire WALTHAM, Mass. , July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...

2023-07-24 08:37:45 ET AMC Entertainment Holdings ( AMC ) +45% give jolt to summer box office. POSCO Holdings  ( PKX ) +17% . Sculptor Capital Management ( SCU ) +16% to acquire Sculptor Capital for $639M. Koss Corporation ( KOSS ) +14% ...

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease PR Newswire – Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg admi...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

2023-06-08 08:29:28 ET Summary Syndax Pharmaceuticals offers a unique investment opportunity in precision oncology with a strong financial standing and commitment to research and development. The company's drug pipeline includes revumenib, axatilimab, and entinostat, which show po...

2023-05-08 22:53:03 ET Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&...